The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

The ENCePP Working Group on Artificial Intelligence in Pharmacoepidemiology and Pharmacovigilance invite stakeholders to contribute to a survey examining the perception and use of artificial intelligence (AI) tools across Pharmacoepidemiology (PE) and Pharmacovigilance (PV).

🎯 Objective of this survey:
To characterise how the ENCePP network and the wider PE/PV community currently employ AI tools in PV/PE, the barriers encountered in practice, and the priorities envisaged for the responsible implementation of AI in PV/PE.
The findings will directly inform the Working Group’s activities, including the development of targeted training, and the establishment of a shared, community-curated inventory of validated AI tools.

πŸ‘₯ Who should participate?
The survey is intended for all professionals engaged in, or adjacent to, PE and PV, irrespective of role, seniority, sector, or prior experience with AI. Specialist expertise in AI is not a prerequisite for participation.

πŸ“Š What will happen after the survey?
The results will be published in scientific articles and reports.

πŸ“‹ Survey details:
πŸ”— Link: https://enceppsurveyai.netlify.app/
πŸ”’ Format: Anonymous, voluntary
⏱️ Time: Approximately 12–15 minutes to complete
πŸ“… Deadline: 30 September 2026

If you want to know more about ENCePP and its work, visit the website: https://encepp.europa.eu/index_en

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752

Privacy Policy

info@cddf.org
Tel: +32 2 880 62 70